Somewhat Positive News Coverage Somewhat Unlikely to Impact Kadmon (KDMN) Stock Price
News articles about Kadmon (NYSE:KDMN) have trended somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies negative and positive news coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Kadmon earned a news impact score of 0.17 on Accern’s scale. Accern also gave headlines about the company an impact score of 45.7447537510859 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
These are some of the headlines that may have effected Accern Sentiment’s rankings:
- Kadmon Holdings Inc (KDMN) Expected to Post Earnings of -$0.34 Per Share (americanbankingnews.com)
- Wired News – Kadmon Presented Updated Positive Results from Phase-2 Study of KD025 in Chronic Graft-Versus-Host Disease at BMT Tandem Meetings (finance.yahoo.com)
- Kadmon (KDMN) Reports Updated Positive Results from Phase 2 Study of KD025 in cGVHD – StreetInsider.com (streetinsider.com)
- Kadmon Holdings Inc (KDMN) Receives Consensus Recommendation of “Hold” from Brokerages (americanbankingnews.com)
Kadmon (NYSE KDMN) opened at $3.63 on Friday. The firm has a market capitalization of $285.47, a price-to-earnings ratio of -2.07 and a beta of 5.59. Kadmon has a 52-week low of $2.05 and a 52-week high of $5.86.
Kadmon Holdings, Inc is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of various unmet medical needs. The Company is developing product candidates in a number of indications within autoimmune and fibrotic disease, oncology and genetic diseases.
Receive News & Ratings for Kadmon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon and related companies with MarketBeat.com's FREE daily email newsletter.